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Abstract
The one-day ETA-CRN meeting, preceding the ETA meeting in Lisbon, was planned in advance to provide a
thorough assessment of the European response to the published American Thyroid Association MTC guidelines.
During the meeting, following each of the European speakers, a series of questions, related to the specific aspect,
were presented to the audience. The responses from the audience were collected by an AudioResponseSystem
(ARS voting system). The results of the voting showed in summary that European expert opinion leaders and an
audience of specialists in treatment of Medullary Carcinoma welcomes the American Guidelines on the
management of MTC, but simultaneously only partially agrees with some of the statements in the guidelines.
Introduction
The one-day ETA-CRN meeting, preceding the ETA
meeting in Lisbon, was planned in advance to provide a
thorough assessment of the European response to the
published American Thyroid Association MTC guide-
lines [1]. This was done by different approaches:
1. A scientific programme was organised starting with a
presentation of the guidelines by Richard Kloos, followed
by European speakers, presenting various aspects of the
guidelines.
2. Before the meeting, following an extensive on-line
discussion among European experts, a series of questions
in relation to the American guidelines were sent to all
presenters, asking for his/her opinion prior to the meet-
ing and the result were presented in Jarzab B et al. Pre-
sentation of points of general discussion and voting
among the speakers [2].
3. During the meeting, following each of the European
speakers, a series of questions, related to the specific
aspect, were presented to the audience. The responses
from the audience were collected by an AudioResponse-
System (ARS voting system). The results of this voting are
summarised below and the full details presented in ques-
tions and answers by the Participants (Additional file 1).
Summary of voting results
The initial questions were asked to identify the individual
members of the audience, and demonstrated that the
audience was 81% Europeans and 83% doctors in clinical
disciplines. The majority of the participants were specia-
lists in medical endocrinology (62%), oncology (11%) or
endocrine/oncological surgery (13%), and most worked
in an academic university hospital (72%).
Only 18% were either not a clinical doctor or a doctor
not treating patients with MTC. The remaining 82%
were equally distributed among those treating >50,
between 10 and 50 and below 10 patients, respectively.
Above basic questions were asked after each break in
order to correctly identify the individual person’s voting
results with that person’s background. The main reason
for that was to try to correlate responses to the back-
ground e.g. differences in response between Europeans
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and others, between clinicians and basic scientists,
between clinicians in medical endocrinology vs oncology
or surgery, between clinicians in university hospitals vs
local hospitals or private praxis etc. This subgrouping was
eventually not performed due to the small numbers in
some of the groups and thus a dominance of others. The
results shown in Additional file 1 only display the first
background voting.
The summary of results is thus based on the audience
as a whole without any subgroups, with some differ-
ences in numbers for each question and at different
parts of the meeting.
The number of actively participating voters is pro-
vided for each question. There were 138 participants.
A total of 39 questions were asked with between 73 and
127 responders.
The present summary of results will mainly highlight the
answers, that demonstrated a discrepancy i.e. when the
European opinion diverged from the American guidelines.
Sixty% of the audience was in favour of measuring
plasma calcitonin in all patients referred for nodular thyr-
oid disease, while 19% would like to see a cost-effectiveness
study, and 21% agreed with the American guidelines (Q1).
Less than half agreed with the ATA guidelines on a fixed
cut-off for serum calcitonin, while the majority would
require local laboratory references (Q2). Sixty-six% were in
favour of performing a pentagastrin stimulation test in all
patients whose serum calcitonin was either low or in the
grey zone. Few agreed with the ATA guidelines (27%)(Q3).
The majority (45%) found that completion thyroidect-
omy is always indicated after an unexpected diagnosis of
MTC, and should be completed by at least central LND,
even if postoperative calcitonin was normal, while 29%
voted for size of the process to decide the procedure, in
disagreement with the ATA recommendations (Q5).
Question Q7 considered the indications for lateral
lymph node surgery and 79% of responders disagreed with
the ATA guidelines, which recommended against prophy-
lactic lateral node dissection irrespective of the central
neck lymph node status. Among them, 46% agreed with a
minority opinion of the American Task Force favouring
prophylactic (elective) lateral neck dissection when lymph
node metastases were present in the adjacent paratracheal
central compartment. However, this question was quite
difficult to be answered and, after questions from the audi-
ence, it was decided by the audience to repeat the voting
with an additional alternative response: (Lateral) lymph
node dissection should be performed if increased basal or
stimulated CT was found in a patient with (after) central
LND. In the repeated voting 32% voted for the added
alternative and in total, 86% of the answers disagreed with
the ATA guidelines. In Q8 there was also a disagreement,
since approx. half of responders found a stimulation test
to be more sensitive than just a basal serum calcitonin
measurement without pentagastrin stimulation. For a
patient with measurable Ct postoperatively, a significant
part of responders (38%) supported very distinctly the cen-
tral CND, if previously not done. Other 54% agreed with
the ATA guideline, also supporting this intervention but
with more caution.
Questions Q9 and Q11-Q18 were related to the staging
and treatment of advanced MTC, generally with significant
agreement with the ATA Guidelines among responders,
ranging between 68% and 84%.
In the third part of the meeting, the guidelines related to
DNA diagnosis and hereditary MTC were discussed (Q19-
Q39). Q 21 illustrates some of the levels of disagreement.
Only one third of participants agreed with the guide-
lines on the desirable extent of RET diagnostics.
This was also the case for 55% of responders, who did
not agree on the narrowing of indications for early test-
ing for MEN 2B, being such a debilitating disease.
According to the European opinion, a RET mutation ana-
lysis should be offered early (Q26). Thirty-seven % of the
European responders were furthermore in favour of
using stimulated serum calcitonin levels to decide on the
time of prophylactic surgery (Q29).
Overall a median of 53% of the audience (Range 14 –
84%) agreed with the American Guidelines, and in gen-
eral between 3 and 9% had no opinion on the specific
question asked. This left roughly 40% in disagreement
with the guidelines.
Among the experts asked ahead of the meeting (data not
shown), the disagreement was even stronger than that of
the audience during the meeting, in particular if leaving
out one expert, who participated in the Task Force. These
results were left out, since they were considered biased
due to the selection of the experts.
Conclusions
European expert opinion leaders and an audience of spe-
cialists in treatment of Medullary Carcinoma welcomes
the American Guidelines on the management of MTC,
but simultaneously only partially agrees with some of the
expressed statements. The results of the survey prior to
the meeting were biased in that the presenters were
selected for presenting the results, but the audience was
present upon open invitation through scientific channels.
Notwithstanding the evidence based guidelines, their
final acceptance requires unrestricted discussion and
consideration of the differences in clinical practice and
experience between countries.
These discussions and results subsequently formed the
basis for establishing a task force within the ETA, and
consequent publication of European guidelines mainly
for the treatment aspects of metastatic MTC.
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Additional material
Additional file 1: Annex 1: Questions and answers by the
participants of the ETA-CRN Session on ATA MTC Guidelines,
Lisbon. (Q indicates question; n indicates the number of voters for
each question)
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